AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21851643 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week physical activity group program with nutritional advice
Number of subjects: 0
Study 21851643 — intervention group
Group type: COMPARATOR
Intervention: Waitlisted group (control)
Number of subjects: 0
Study 19148642 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini incision (<10 cm)
Number of subjects: 62
Study 19148642 — intervention group
Group type: COMPARATOR
Intervention: Standard incision (15 cm)
Number of subjects: 62
Study 17214932 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvia miltiorrhiza
Number of subjects: 36
Study 17214932 — intervention group
Group type: COMPARATOR
Intervention: Non-Salvia miltiorrhiza treatment
Number of subjects: 36
Study 17214932 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control)
Number of subjects: 36
Study 15019333 — intervention group
Group type: EXPERIMENTAL
Intervention: Arteriovenous sheathotomy surgery
Number of subjects: 20
Study 15019333 — intervention group
Group type: COMPARATOR
Intervention: Control (observation and laser treatment)
Number of subjects: 20
Study 11352445 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid 500mg twice daily for 2 days before moxifloxacin
Number of subjects: 12
Study 11352445 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400mg
Number of subjects: 12
Study 9165133 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with cisplatin (100 mg/m2 i.v. infusion on day 1) and 5-fluorouracil (1000 mg/m2 continuous i.v. infusion for 120 hours) followed by radiotherapy (64-70 Gy in 2 Gy per fraction, 5 times/week)
Number of subjects: 461
Study 9165133 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (radiotherapy or radiotherapy followed by surgery)
Number of subjects: 461
Study 9165133 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil followed by radiotherapy
Number of subjects: 461
Study 7970935 — intervention group
Group type: EXPERIMENTAL
Intervention: L-[2-15N]glutamine infusion
Number of subjects: 11
Study 7970935 — intervention group
Group type: COMPARATOR
Intervention: Control group (4 infants)
Number of subjects: 11
Study 7970935 — intervention group
Group type: EXPERIMENTAL
Intervention: L-[1-13C]leucine infusion
Number of subjects: 11
Study 3658434 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate (0.5%)
Number of subjects: 17
Study 3658434 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 17
Study 29196938 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral nerve block (PNB)
Number of subjects: 0
Study 29196938 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia (subarachnoid block - SAB)
Number of subjects: 0
Study 28914366 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric assessment (GA) with management interventions
Number of subjects: 71
Study 28914366 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 71
Study 27734719 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial oocyte activation (AOA)
Number of subjects: 21
Study 27734719 — intervention group
Group type: COMPARATOR
Intervention: Control group (no AOA)
Number of subjects: 21
Study 24595568 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical clofibrate
Number of subjects: 20
Study 22618956 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-coated sutures
Number of subjects: 276
Study 22618956 — intervention group
Group type: COMPARATOR
Intervention: Noncoated sutures
Number of subjects: 276
Study 21194422 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate/sulphamethoxypyrazine/pyrimethamine (AS + SMP)
Number of subjects: 500
Study 21194422 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate/amodiaquine (AS + AQ)
Number of subjects: 500
Study 18245032 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine plus carbamazepine (10-30 mg/day plus 400-1200 mg/day)
Number of subjects: 118
Study 18245032 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus carbamazepine (400-1200 mg/day)
Number of subjects: 118
Study 16040445 — intervention group
Group type: EXPERIMENTAL
Intervention: SB (Single Bond)
Number of subjects: 24
Study 16040445 — intervention group
Group type: EXPERIMENTAL
Intervention: NaOCl/SB (Sodium Hypochlorite + Single Bond)
Number of subjects: 24
Study 16040445 — intervention group
Group type: EXPERIMENTAL
Intervention: SB/PL (Single Bond + Protect Liner)
Number of subjects: 24
Study 16040445 — intervention group
Group type: EXPERIMENTAL
Intervention: NaOCl/SB/PL (Sodium Hypochlorite + Single Bond + Protect Liner)
Number of subjects: 24
Study 11969360 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime (100 mg/kg/day) IV
Number of subjects: 40
Study 11969360 — intervention group
Group type: COMPARATOR
Intervention: Dicloxacillin (200 mg/kg/day) plus Chloramphenicol (100 mg/kg/day) IV
Number of subjects: 40
Study 10401446 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20-30 mg/day)
Number of subjects: 81
Study 10401446 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (adjusted to plasma concentration of 50-150 ng/ml)
Number of subjects: 81
Study 8930007 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 732
Study 8930007 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 732
Study 2042462 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood donation prior to hip arthroplasty
Number of subjects: 60
Study 2042462 — intervention group
Group type: COMPARATOR
Intervention: Control group (no phlebotomy)
Number of subjects: 60
Study 7240807 — intervention group
Group type: EXPERIMENTAL
Intervention: Subvirion influenza B vaccine (500 chick cell‐agglutinating units)
Number of subjects: 0
Study 7240807 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole‐virus influenza B vaccine
Number of subjects: 0
Study 7240807 — intervention group
Group type: EXPERIMENTAL
Intervention: Subvirion influenza B vaccine
Number of subjects: 0
Study 30591465 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI with 100 mg erlotinib daily on days 3-8 after each infusion every 14 days
Number of subjects: 58
Study 30591465 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 with 100 mg erlotinib daily on days 3-8 after each infusion every 14 days
Number of subjects: 58
Study 30407328 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric blankets set to 38°C (group E)
Number of subjects: 443
Study 30407328 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warmer set to 38°C (group F)
Number of subjects: 443
Study 30407328 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warmer plus electric blankets set to 38°C (group FE)
Number of subjects: 443
Study 30407328 — intervention group
Group type: COMPARATOR
Intervention: Control group (group E)
Number of subjects: 443
Study 30407328 — intervention group
Group type: COMPARATOR
Intervention: Control group (group F)
Number of subjects: 443
Study 30407328 — intervention group
Group type: COMPARATOR
Intervention: Control group (group FE)
Number of subjects: 443
Study 26929803 — intervention group
Group type: EXPERIMENTAL
Intervention: Large drain (LD, 2.8‐mm‐diameter tube)
Number of subjects: 77
Study 26929803 — intervention group
Group type: COMPARATOR
Intervention: Small drain (SD, 1.6‐mm‐diameter tube)
Number of subjects: 77
Study 24433926 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNβ‐1a i.m. weekly injected (group a)
Number of subjects: 394
Study 24433926 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNβ‐1a 44 μg s.c. injected three times a week (group b)
Number of subjects: 394
Study 24433926 — intervention group
Group type: COMPARATOR
Intervention: Untreated (group c)
Number of subjects: 394
Study 23103963 — intervention group
Group type: EXPERIMENTAL
Intervention: Freely evolving decision variable signal
Number of subjects: 0
Study 23103963 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic perturbation of the decision variable signal
Number of subjects: 0
Study 23103963 — intervention group
Group type: EXPERIMENTAL
Intervention: Domain general decision variable signal
Number of subjects: 0
Study 19056572 — intervention group
Group type: EXPERIMENTAL
Intervention: FS50 (50 g/day, 264 kcal)
Number of subjects: 182
Study 19056572 — intervention group
Group type: COMPARATOR
Intervention: LP (maize-soy flour, 71 g/day, 282 kcal)
Number of subjects: 182
Study 19056572 — intervention group
Group type: EXPERIMENTAL
Intervention: FS25 (25 g/day, 130 kcal)
Number of subjects: 182
Study 17490492 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visiting intervention with eight visits from a specially trained community nurse over two years and pro-active telephone support.
Number of subjects: 782
Study 16802211 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser therapy (EVLT)
Number of subjects: 132
Study 16802211 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 132
Study 16802211 — intervention group
Group type: COMPARATOR
Intervention: Endovenous laser therapy (EVLT) and Surgery
Number of subjects: 132
Study 12957433 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 20
Study 10664643 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained group (n = 50) received a training booklet in the mail 2 to 3 days prior to the scheduled appointment.
Number of subjects: 150
Study 10664643 — intervention group
Group type: COMPARATOR
Intervention: Informed group (n = 49) received a brief written summary of the major points contained in the training booklet while in the waiting room prior to the scheduled appointment.
Number of subjects: 150
Study 10664643 — intervention group
Group type: COMPARATOR
Intervention: Untrained group (n = 51) did not receive any form of communication skills intervention.
Number of subjects: 150
Study 8862762 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute bed-rest regime for 7 days
Number of subjects: 30
Study 8862762 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigorous bed-rest regime for 7 days
Number of subjects: 30
Study 8862762 — intervention group
Group type: COMPARATOR
Intervention: Normal ambulatory conditions (control group)
Number of subjects: 30
Study 1340807 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 0
Study 1340807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6347985 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation for 6 weeks
Number of subjects: 20
Study 6347985 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 20
Study 31708999 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer counselling intervention with a 10-day training course including practical sessions on breastfeeding techniques and challenges.
Number of subjects: 17
Study 31708999 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer counselling intervention
Number of subjects: 17
Study 29803534 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 500 mg (therapeutic dose)
Number of subjects: 48
Study 29803534 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 750 mg (supratherapeutic dose)
Number of subjects: 48
Study 29803534 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 48
Study 29803534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 29803534 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 500 mg after high-fat food intake
Number of subjects: 48
Study 29803534 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin (both doses)
Number of subjects: 48
Study 27299459 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuefu Zhuyu Capsule (XFZY-CS) at 2.5% concentration
Number of subjects: 6
Study 27299459 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuefu Zhuyu Capsule (XFZY-CS) at 5% concentration
Number of subjects: 6
Study 27299459 — intervention group
Group type: COMPARATOR
Intervention: Reverse signaling activator EphB4/Fc
Number of subjects: 6
Study 27299459 — intervention group
Group type: COMPARATOR
Intervention: PP2 (pyrophosphatase/phosphodiesterase2)
Number of subjects: 6
Study 23712439 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting survival
Number of subjects: 1614
Study 23712439 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram
Number of subjects: 1614
Study 22342450 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month family-based behavioral intervention
Number of subjects: 270
Study 22342450 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive recruitment methods (mailings, TV ads, pamphlets)
Number of subjects: 270
Study 19557206 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast as add-on therapy
Number of subjects: 320
Study 17577134 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 500 mg preoperatively
Number of subjects: 73
Study 17577134 — intervention group
Group type: COMPARATOR
Intervention: Control group (no methylprednisolone)
Number of subjects: 73
Study 16354313 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (n=142; 4 cycles of cisplatin 75 mg/m2 I.V. on day 1 with etoposide 100 mg/m2 I.V. on days 1-3 followed by 4 cycles of topotecan 1.5 mg/m2 I.V. on days 1-5)
Number of subjects: 284
Study 16354313 — intervention group
Group type: COMPARATOR
Intervention: Alternating therapy (n=142; same doses of cisplatin/etoposide on cycles 1, 3, 5, and 7 and topotecan on cycles 2, 4, 6, and 8)
Number of subjects: 284
Study 11880130 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) from Norplant users
Number of subjects: 40
Study 11880130 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel (LNG) from IUD users
Number of subjects: 40
Study 10434322 — intervention group
Group type: COMPARATOR
Intervention: Group 1: No particular advice, possible referral for consultation
Number of subjects: 45
Study 10434322 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: Systematic referral for consultation 3 months post-surgery
Number of subjects: 45
Study 10434322 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: Planned consultation and test injection before surgery
Number of subjects: 45
Study 7770366 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 0
Study 2277574 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenylhydantoin (DPH) 2.5 mg kg‐1
Number of subjects: 54
Study 2277574 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐Tubocurarine (d‐TC) 50 micrograms kg‐1
Number of subjects: 54
Study 2277574 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 54
Study 2277574 — intervention group
Group type: COMPARATOR
Intervention: All groups (including Control)
Number of subjects: 54
Study 7026817 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 65
Study 7026817 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 65
Study 7026817 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoprofen calcium
Number of subjects: 65
Study 7026817 — intervention group
Group type: COMPARATOR
Intervention: Various NSAIDs
Number of subjects: 65
Study 7026817 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred medication
Number of subjects: 65
Study 31433343 — intervention group
Group type: EXPERIMENTAL
Intervention: Music with binaural beats (BB) for 30 minutes before sleep
Number of subjects: 43
Study 31433343 — intervention group
Group type: COMPARATOR
Intervention: Music only (control group) for 30 minutes before sleep
Number of subjects: 43
Study 31433343 — intervention group
Group type: EXPERIMENTAL
Intervention: Music with binaural beats (BB)
Number of subjects: 43
Study 31433343 — intervention group
Group type: COMPARATOR
Intervention: Music only (control group)
Number of subjects: 43
Study 28476132 — intervention group
Group type: EXPERIMENTAL
Intervention: rebamipide 2% liquid
Number of subjects: 94
Study 28476132 — intervention group
Group type: EXPERIMENTAL
Intervention: rebamipide 4% liquid
Number of subjects: 94
Study 28476132 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 94
Study 26491878 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural support plus a PA intervention (supervised treadmill exercise plus PA consultations)
Number of subjects: 785
Study 26491878 — intervention group
Group type: COMPARATOR
Intervention: Behavioural support alone (control)
Number of subjects: 785
Study 26491878 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural support plus a PA intervention
Number of subjects: 785
Study 23384634 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual assessment of brain MRI in heart failure patients
Number of subjects: 67
Study 23384634 — intervention group
Group type: COMPARATOR
Intervention: Visual assessment of brain MRI in control subjects
Number of subjects: 67
Study 21489817 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 months of valganciclovir prophylaxis
Number of subjects: 38
Study 21489817 — intervention group
Group type: COMPARATOR
Intervention: 3 months of valganciclovir prophylaxis
Number of subjects: 38
Study 19552876 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching primer (SEP)
Number of subjects: 34
Study 19552876 — intervention group
Group type: COMPARATOR
Intervention: Conventional acid-etched technique with Transbond (control)
Number of subjects: 34
Study 17367439 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 121
Study 17367439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 15033254 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline N-terminal proatrial natriuretic peptide (Nt-proANP)
Number of subjects: 71
Study 15033254 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month changes in end-diastolic volume index
Number of subjects: 71
Study 15033254 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month E/A ratio
Number of subjects: 71
Study 15033254 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Nt-proANP
Number of subjects: 71
Study 15033254 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal velocity of systolic pulmonary venous flow
Number of subjects: 71
Study 15033254 — intervention group
Group type: COMPARATOR
Intervention: End-diastolic volume index
Number of subjects: 71
Study 15033254 — intervention group
Group type: COMPARATOR
Intervention: End-systolic volume index
Number of subjects: 71
Study 11346831 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT) plus manual therapy of the cervical spine (group I)
Number of subjects: 30
Study 11346831 — intervention group
Group type: COMPARATOR
Intervention: Low-energy shockwave therapy (group II)
Number of subjects: 30
Study 9914664 — intervention group
Group type: EXPERIMENTAL
Intervention: Low self-esteem individuals
Number of subjects: 0
Study 9914664 — intervention group
Group type: EXPERIMENTAL
Intervention: High self-esteem individuals
Number of subjects: 0
Study 7822903 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethylrutosides (1 g twice daily for 4 weeks)
Number of subjects: 0
Study 7822903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3126638 — intervention group
Group type: EXPERIMENTAL
Intervention: NTG oral spray (0.8 mg) in hydrosoluble solution (NTG-h)
Number of subjects: 20
Study 3126638 — intervention group
Group type: EXPERIMENTAL
Intervention: NTG oral spray (0.8 mg) in liposoluble solution (NTG-I)
Number of subjects: 20
Study 3126638 — intervention group
Group type: EXPERIMENTAL
Intervention: NTG oral spray (both formulations)
Number of subjects: 20
Study 31055452 — intervention group
Group type: COMPARATOR
Intervention: double‐freeze CO2 cryotherapy (referent)
Number of subjects: 127
Study 31055452 — intervention group
Group type: EXPERIMENTAL
Intervention: single‐freeze CO2 cryotherapy
Number of subjects: 127
Study 31055452 — intervention group
Group type: EXPERIMENTAL
Intervention: double‐freeze CryoPen
Number of subjects: 127
Study 31055452 — intervention group
Group type: EXPERIMENTAL
Intervention: single‐freeze CryoPen
Number of subjects: 127
Study 31055452 — intervention group
Group type: EXPERIMENTAL
Intervention: thermoablation
Number of subjects: 127
Study 29118031 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol succinate
Number of subjects: 121
Study 29118031 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 121
Study 29118031 — intervention group
Group type: COMPARATOR
Intervention: Anthracycline therapy
Number of subjects: 121
Study 26580081 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive cognitive bias modification training for interpretation (CMB‐I)
Number of subjects: 87
Study 26580081 — intervention group
Group type: COMPARATOR
Intervention: Neutral training
Number of subjects: 87
Study 22239608 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Number of subjects: 35
Study 22239608 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics
Number of subjects: 35
Study 21636566 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (250 mg)
Number of subjects: 20
Study 21636566 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg)
Number of subjects: 20
Study 21636566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21636566 — intervention group
Group type: EXPERIMENTAL
Intervention: AMS-resistant subjects
Number of subjects: 20
Study 21636566 — intervention group
Group type: EXPERIMENTAL
Intervention: AMS-susceptible subjects
Number of subjects: 20
Study 18086027 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-based (RB) sealant
Number of subjects: 599
Study 18086027 — intervention group
Group type: COMPARATOR
Intervention: Glass ionomer cement (GIC) sealant
Number of subjects: 599
Study 17062971 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral oxyhemoglobin (O(2)Hb) during exercise in patients with IDC
Number of subjects: 42
Study 17062971 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral tissue oxygenation index (TOI) during exercise in patients with IDC
Number of subjects: 42
Study 17062971 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral O(2)Hb in patients with reduced consciousness during exercise recovery
Number of subjects: 42
Study 17062971 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral TOI in patients with reduced consciousness during exercise recovery
Number of subjects: 42
Study 17062971 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral O(2)Hb in patients with ventricular tachycardia
Number of subjects: 42
Study 17062971 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral TOI in patients with ventricular tachycardia
Number of subjects: 42